Da man har benyttet afbrudte behandlingsperioder i de kliniske afprøvninger, ved man ikke om aftrapning af doseringen vil kunne reducere hyppigheden af recidiver.
As clinical efficacy studies were performed with abrupt cessation of treatment, no information is available on whether tapering of the dosage would reduce recurrence rate.